Picture of Arbutus Biopharma logo

ABUS Arbutus Biopharma Income Statement

0.000.00%
us flag iconLast trade - 00:00
HealthcareAdventurousMid CapMomentum Trap

Annual income statement for Arbutus Biopharma, fiscal year end - December 31st, USD millions except per share, conversion factor applied.

C2019
December 31st
2020
December 31st
2021
December 31st
2022
December 31st
2023
December 31st
Period Length:12 M12 M12 M12 M12 M
Source:10-K10-K10-K10-K10-K
Standards:
USG
USG
USG
USG
USG
Status:FinalFinalFinalFinalFinal
Revenue
Total Revenue6.016.91113918.1
Selling / General / Administrative Expenses
Research And Development
Depreciation and Amortization
Unusual Expense / Income
Other Operating Expenses
Total Operating Expenses15064.784.510496.2
Operating Profit-144-57.8-73.5-65.5-78.1
Total Net Non Operating Interest Income / Expense
Net Income Before Taxes-166-63.7-76.2-65-72.8
Provision for Income Taxes
Net Income After Taxes-154-63.7-76.2-69.5-72.8
Net Income Before Extraordinary Items
Net Income-154-63.7-76.2-69.5-72.8
Adjustments to Net Income
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income-165-75.9-88.4-69.5-72.8
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS-2.06-1-0.832-0.46-0.439